What Medomie does

Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to commercialize Verrica Pharmaceuticals' YCANTH (VP-102) topical treatment for molluscum contagiosum within the Israeli market. Under the distribution agreement announced in July 2026, Verrica manufactures and supplies the product while Medomie is responsible for pursuing local regulatory approval and distributing YCANTH in Israel. The agreement entitles Verrica to 60% of net sales and grants Medomie eligibility for combined milestone payments of up to $8.2 million, alongside the remaining 40% net sales share.

The company's operating model is structured as a single-product, single-geography distribution entity with 1-10 employees. Its core function is regulatory navigation and channel access for a single approved dermatology therapeutic in Israel, rather than drug discovery or manufacturing. Verrica retains exclusive global rights to YCANTH outside of Japan and Israel, bounding Medomie's addressable market to the Israeli patient population for molluscum contagiosum.

Medomie's go-to-market is exclusively through its partnership channel with Verrica; there is no evidence of additional in-house sales infrastructure beyond what is needed to execute this single distribution mandate. Revenue, once generated, derives from 40% of YCANTH net sales in Israel plus contingent milestone payments, contingent on Israeli regulatory approval being secured. The company has no publicly disclosed funding rounds, ownership structure, or management team in the available sources.

Name

Medomie

Legal name

Medomie

Website

https://medomie.co.il

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to seek regulatory approval for and distribute Verrica Pharmaceuticals' YCANTH (VP-102) treatment for molluscum contagiosum in the Israeli market.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Others

Revenue model

1. Distribution of YCANTH: Medomie distributes YCANTH for molluscum contagiosum in Israel. Verrica manufactures and supplies the product, receiving 60% of net sales. Medomie's revenue comes from the remaining 40% of net sales plus potential milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Medomie is an Israeli pharmaceutical distribution company that holds exclusive rights from Verrica Pharmaceuticals to seek regulatory approval and distribute YCANTH (VP-102), a topical treatment for molluscum contagiosum, in the Israeli market. The company handles local regulatory filings and commercialization while Verrica manufactures and supplies the product under a revenue-share arrangement.

Product overview

Medomie Pharma is a pharmaceutical distribution company focused on bringing dermatological therapeutics to the Israeli market. The company operates as a single-product distribution entity, holding exclusive rights to distribute Verrica Pharmaceuticals' YCANTH (VP-102) for molluscum contagiosum in Israel. Under the distribution agreement, Verrica manufactures and supplies the product while Medomie handles regulatory approval and commercialization locally, with Verrica receiving 60% of net sales and up to $8.2 million in milestone payments.

Differentiator

Problem solved

Functional benefit

Products and services

• YCANTH (VP-102) YCANTH (VP-102) is a topical treatment for molluscum contagiosum. Medomie Pharma holds exclusive distribution rights for the Israeli market, where it seeks regulatory approval and distributes the product, with Verrica manufacturing and supplying the treatment.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Verrica PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 21 July 2026Medomie Pharma entered an exclusive distribution agreement with Verrica Pharmaceuticals granting Medomie rights to seek regulatory approval and distribute YCANTH for molluscum contagiosum in Israel. Verrica manufactures and supplies the product, receiving 60% of net sales. Medomie is eligible to receive up to $8.2 million in combined regulatory and commercial milestones. Verrica retains exclusive global rights to YCANTH outside of Japan and Israel.

Scale indicators2 records

Recent moves1 record

Expansion highlights3 records

Direct peers

• RedHill Biopharma: Israeli specialty biopharmaceutical company that in-licenses and commercializes therapeutics, with a strong focus on distribution partnerships and out-licensing. Comparable to Medomie in its in-licensing/distribution business model targeting international pharma assets.
• Sol-Gel Technologies: Israeli clinical-stage dermatology-focused pharmaceutical company developing topical treatments. Comparable to Medomie in its Israeli base and dermatology therapeutic focus, with overlapping physician and channel relationships.
• Dexcel Pharma: Israeli specialty pharmaceutical company that licenses, develops, and distributes therapeutics in the Israeli market. Comparable to Medomie as a domestically focused Israeli pharma commercialization/distribution entity serving as a local partner for foreign innovators.
• Kamada Ltd. Israeli specialty pharmaceutical company that develops, manufactures, and commercializes specialty therapeutics, with significant distribution and licensing activities in Israel. Comparable in its Israeli specialty pharma distribution and in-licensing model.

Emerging players

• Vyne Therapeutics: Israeli-founded dermatology-focused pharmaceutical company developing topical therapeutics. Comparable to Medomie in its dermatology focus and Israeli origin, with overlapping physician targets in the local dermatology community.
• BioLineRx: Israeli clinical-stage biopharmaceutical company that in-licenses and develops therapeutic candidates, often partnering with larger pharma for commercialization. Comparable in its Israeli base and in-licensing/partnership-driven business model.
• PolyPid Ltd. Israeli clinical-stage specialty pharmaceutical company developing innovative therapeutics with commercialization intended in part through distribution partnerships. Comparable to Medomie as a small Israeli specialty pharma with partnership-driven commercialization.

Broad incumbents

• Taro Pharmaceutical Industries: Israeli-founded multinational generic and specialty pharmaceutical manufacturer with established Israeli distribution operations. Comparable as a large incumbent Israeli pharma player that distributes therapeutics through local channels.
• Teva Pharmaceutical Industries: Global pharmaceutical company headquartered in Israel with broad specialty, generic, and distribution operations. Comparable as the dominant Israeli pharma incumbent against which smaller specialty distributors like Medomie compete for channel and physician access.
• Perrigo Company: Global consumer healthcare and specialty pharmaceutical company with established operations and distribution in Israel. Comparable as a larger incumbent with Israeli distribution presence in dermatology-adjacent therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/medomie

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medomie